Baxter International (BAX) : On Tuesday, The money flowed into the Baxter International (BAX) stock with an uptick to downtick ratio was recorded at 1.55. Transactions worth $19.42 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $12.55 million. The total money flow into the stock was $6.87 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $5.11 million of block transactions on upticks. The total money flow in block trades was $5.11 million. In terms of price action, Baxter International (BAX) traded down $0.16 during the session at $46.49. Compared to the previous days closing, the stock was down only by -0.34%. For the week, the stock is 2.29%, over previous weeks closing.
The company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 84.71% of Baxter International shares. During last six month period, the net percent change held by insiders has seen a change of -23.18%. In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Baxter International Inc, Almeida Jose E, had purchased 11,691 shares in a transaction dated on May 23, 2016. The transaction was executed at $42.75 per share with total amount equaling $499,790.
Shares of Baxter International Inc. rose by 3.4% in the last five trading days and 5.3% for the last 4 weeks. Baxter International Inc. is up 11.8% in the last 3-month period. Year-to-Date the stock performance stands at 23.53%.
Baxter International (NYSE:BAX): stock turned positive on Tuesday. Though the stock opened at $46.5, the bulls momentum made the stock top out at $47.135 level for the day. The stock recorded a low of $46.39 and closed the trading day at $46.85, in the green by 0.77%. The total traded volume for the day was 3,544,654. The stock had closed at $46.49 in the previous days trading.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.